Tripokin (IL2-L19-TNF) is a fully-human immunostimulatory product consisting of the human vascular targeting antibody L19 that recognizes the alternatively spliced EDB domain of fibronectin, simultaneously fused to both human interleukin 2 (IL2) and human tumor necrosis factor alpha (TNFa). IL2 is a cytokine that stimulates immune effector cells, while TNF is a strong pro-inflammatory cytokine.
Considering that TNF is ten times more potent than IL2, to match the biological activity of the two cytokines a single point mutation in the TNF moiety was introduced.
The rationale for the development of this product relies on the fact that the combination of IL2- and TNF- based immunocytokines showed a strong synergistic effect in both pre-clinical and clinical studies.


De Luca et al. (2017) Mol Cancer Ther, 16(11); 2442–51;
Danielli et al. (2015) Cancer Immunol. Immunother. 64, 999-1009;
Hemmerle and Neri (2013) Br. J. Cancer 109 (5) 1206-13;
Schwager et al. (2013) J. Invest. Dermatol., 133, 751-8;
Papadia et al. (2013) J Surg Oncol., 107, 173-179;
Eigentler et al. (2011) Clin. Cancer Res., 17, 7732-42;
Balza et al. (2006) Clin. Cancer Res., 12, 2575-2582;
Borsi et al. (2003) Blood, 102, 4384-4392.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy